Skip to content
Central Laboratories

Medpace Central Labs Expand Singapore Facility

  • October 18, 2023

Medpace Central Laboratories has had a tenured presence in Asia Pacific since 2009, operating in Singapore since 2014, serving as a pivotal hub for clinical research in the region. As part of our continuous effort to enhance our capabilities and better serve our Sponsors, we are proud to announce an expansion of our Singapore facility.

Facility Expansion and Metrics

Our Singapore lab, as well as our other global laboratory locations in the US, Belgium, and China, are wholly-owned and purpose-built with state-of-the-art infrastructure. They have the same testing instrumentation, adhere to global operating procedures, and utilize a global laboratory information system.

Encompassing both laboratory and office spaces, the new Singapore facility covers 35,454 square feet – a 62% increase in size. Strategically located just 20 minutes away from Changi Airport, this location streamlines shipment receipt, ensuring projects stay on schedule and meet deadlines efficiently.

Medpace Singapore Testing Capabilities

  • Molecular and Genomics
    • Viral load, respiratory viruses and C. diff testing
    • Genotyping (Sanger and qPCR), Fragment Analysis and MLPA available in mid-2024
    • NGS panels, germline exome and metagenomics available in late-2024
  • Flow Cytometry
    • Custom Panels
      • Receptor occupancy assays
      • Immune cell phenotyping and Immune cell function assays
      • Intracellular cytokine assays
      • Functional assays
    • Standard Panels
      • TBNK
      • PNH
      • CD34+ stem cell count
      • T Cell exhaustion
      • CD4/CD8
      • NK
      • DC panel
      • Monocyte panel
      • B Cell Panel
      • Intracellular cytokine panel
  • Safety Testing
    • Chemistry, hematology, urinalysis, serology, and coagulation
  • Biomarkers
    • Ligand-binding (ELISA) assays
    • Automated immunoassays
    • Nephelometry
    • Lipid biomarkers (including preparative ultracentrifugation for lipid analyses)
  • Histology & Anatomic Pathology
    • Infrastructure built in this new facility for future growth of tissue processing and staining at the Singapore lab
  • Biorepository Services  
    • 434 square meter onsite biorepository department 
    • PBMC processing 
    • Storage conditions for ambient, refrigerated, -20C, and -70C   
    • Storage of serum, plasma, urine, DNA, RNA, biopsies/slides, and PBMC  
    • Monitored 24/7/365 
  • Testing supporting trials in the following therapeutic areas
    • Infectious Diseases
    • Cardiology/Vascular Diseases
    • CNS/Neurology
    • Endocrinology/Metabolic
    • Gastroenterology
    • Hematology/Oncology
    • Immunology
    • Nephrology/Urology

Medpace Singapore Leadership Team

Medpace’s Singapore laboratory is led by both an experienced on-site Laboratory Director and Laboratory Manager and is staffed by technologists who have combined decades of experience in central laboratory testing. Our on-site Project Managers oversee studies conducted in Asia Pacific and are integrated into the global project management team. Additionally, the laboratory has strong leadership to manage local operations and to ensure alignment with Medpace’s global processes.

Paul Thiam Joo Tan, PhD

Director, Clinical Laboratory Services, Asia Pacific

  • 15+ years’ experience in direct research and development within a clinical laboratory
  • Associate Faculty researching on T-cell DNA influenza vaccine at Johns Hopkins University, Baltimore, USA
  • Experienced in the direct management and operations of multi-country laboratories to ensure safe, cost-effective productivity and quality in all laboratory operations
  • Previously served as laboratory director for laboratories in Singapore, Hong Kong, and Indonesia
  • Therapeutic area experience includes Next-Generation Sequencing in pathology and oncology, genomics, immunology, blood stem cell banking, infectious diseases and molecular diagnostics

Hiren Patel, Bsc, Msc

Senior Laboratory Manager, Medpace Singapore

  • Over 15 years of experience in various clinical laboratory therapeutic areas including safety and biomarker testing
  • Affiliated with Medpace since 2009 and actively contributed to the establishment of central laboratories in India (2009) and Singapore (2014 and 2023)
  • Knowledge of national and international central laboratory regulatory requirements e.g. CAP, HCSA (MOH), GCLP etc.

Birender Kumar, BMLT, BSc Biochemistry

Biorepository Manager/Laboratory Supervisor, Medpace Singapore

  • Joined Medpace in 2009, Proficient individual with management experience and strong leadership skills
  • Seasoned Medical Technologist with rich bench experience in Laboratory sections and responsible for Biorepository operations in Singapore
  • 18 years of clinical laboratory experience in diagnostic and clinical trial laboratories in India and Singapore
  • Instrumental in getting all national and international Accreditations/Certifications for Medpace Laboratories

Asia Pacific Drug Development Services

As a global CRO with an operational footprint across 40 countries, Medpace has broad experience designing and conducting Phase I-IV clinical trials around the world. Our medical, regulatory, and operational experts have the resources to advance your medical therapeutic in any region. Since establishing our Asia Pacific presence in 2004, our medical and operational specialists have country-specific expertise, which allows them to integrate local language, culture, and requirements into study conduct, to deliver faster enrollment, and obtain access to country-specific patient populations. Our regulatory experts can plan and coordinate each aspect of regulatory strategy and engagement – locally and globally.

Learn more about Medpace’s central laboratory and Asia Pacific capabilities.